Zimmer Biomet Holdings, Inc.

ZBH · NYSE · USD

Will converting the U.S. sales force from independent distributors to dedicated employees return Zimmer Biomet to durable mid-single-digit growth, or keep it below the orthopedic market?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Product cycle gaining traction

    The bull case is that the new product cycle is working, with hips, robotics and extremities growing faster than the market while the channel is rebuilt.

  • Guidance raised during transition

    Management raised its full-year sales outlook after a strong first half, which supports the view that converting the sales force is costing less growth than planned.

  • Cash generation funds buybacks

    Free cash flow grows every year and most of it goes back to shareholders through buybacks, so earnings per share can rise even when revenue growth is modest.

  • Premium-priced new products

    New implants such as the iodine-coated hip and the Monogram robot give the company products it can charge more for and a route into faster-growing procedures.

Bear case

  • Channel conversion drags growth

    The bear case is that the sales force conversion runs through next year, so growth stays below the orthopedic market and the promised acceleration keeps slipping.

  • Knee franchise losing share

    Knees are the largest franchise and have stopped growing, which offsets faster growth in hips and robotics and leaves the company relying on smaller businesses.

  • Margins falling with volume

    Slower volume growth is pulling gross margin down, so profit per share depends more on cost cuts and buybacks than on the underlying business improving.

  • Pricing pressure from payors

    Pricing has moved from flat to a headwind as hospitals and payors push back, which limits how much new products can add to revenue.

Bull and bear points

Growth & Execution

In short: Hips, robotics and extremities grow well; flat knees and a channel rebuild keep total growth under market.

Bull · 1

  • Full-year sales guidance raised after a strong first half

    In February management guided 2026 organic growth to 1% to 3% for a year it called transitional; it now guides 2.25% to 3.25%. That suggests the channel changes are costing less growth than planned.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Knees, the largest franchise, has stopped growing

    Knee sales of $829 million rose only 0.4% year on year, and international knees fell. The biggest revenue line is adding nothing, and hips and robotics are not yet large enough to offset it.

    Filed financials

  • Total growth is guided below the market it competes in

    Management puts orthopedic market growth at 4% to 5% but guides the company below that, so any improvement depends on taking share during a channel rebuild that runs to the end of 2027.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Free cash flow and buybacks support per-share results, while margins fall as volume growth slows.

Bull · 2

  • Free cash flow keeps growing faster than sales

    Free cash flow was $1.5 billion over the past year, 17.9% of revenue, and management expects 9% to 11% growth in 2026 as inventory days on hand come down.

    Q2 FY2026 call

  • Buybacks and dividends absorb most of free cash flow

    The company returned $939 million over the past year, 62% of free cash flow, and plans up to $1 billion of buybacks in 2026. That lifts earnings per share even when revenue growth is slow.

    Q2 FY2026 call
Bear · 2

  • Gross margin falls as volume growth slows

    Gross margin was 70.8%, down from 71.5% a year earlier, and management guides the year to about 71% while adding spending in the U.S. channel, so operating margin falls as well.

    Q2 FY2026 call

  • First-quarter earnings beat leaned on tariff items

    About $0.20 a share of the first-quarter beat came from tariff-related items rather than operations, so the underlying earnings growth was smaller than the reported figure.

    Q1 FY2026 call

Market Position

In short: It has the only cementless partial knee and premium iodine hips, but payor pressure limits pricing.

Bull · 2

  • Iodine-coated hips command a premium price in Japan

    The iodine hip launched in Japan, the company's second-largest market, and management says demand is outrunning supply. A new implant class sold at a higher price supports revenue and margin at once.

    Q4 FY2025 call

  • Only company with a cementless partial knee and shoulder robot

    Oxford Partial Cementless is the only partial cementless knee approved in the U.S., and ROSA Shoulder is the only robot that performs both anatomic and reverse shoulder replacements, which supports pricing and account conversions.

    Q2 FY2026 call
Bear · 1

  • Pricing has swung from flat to a clear headwind

    A year ago consolidated pricing was slightly positive; in the second quarter it was an 80 basis point headwind, and management allows up to 100 basis points of erosion for the year.

    Tone shiftQ3 FY2025 → Q2 FY2026